Elsevier Launches International Journal for Parasitology: Drugs and Drug Resistance
AMSTERDAM, June 22, 2011 /PRNewswire/ --
New Open Access Journal Dedicated to Collaborations and Cutting-Edge Research in Parasitology
Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, in association with the Australian Society for Parasitology, is pleased to announce the launch of a new journal, International Journal for Parasitology: Drugs and Drug Resistance. The new electronic open access journal is closely affiliated with the leading parasitology journal, International Journal for Parasitology, and will address a critical area of research, covering anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal's remit also includes research into natural products as anti-parasitic agents, and bioactive parasite products.
Prof Terry Spithill, President of the Australian Society for Parasitology, said, "The Society is delighted to have fostered the founding of this new Journal which we anticipate will provide a stellar forum for the dissemination of original discoveries in the pharmacological control of parasites of human and veterinary significance."
Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. The Journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions". Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.
"We are delighted to continue our excellent relationship with the Australian Society for Parasitology, and are confident that IJP:DDR will quickly establish itself as the leading journal in its field," added Dale Seaton, Executive Publisher for Elsevier. "In addition, by utilizing the open access model option for this title, Elsevieris enabling the broadest possible access to quality research content in a sustainable way that meets the society's needs."
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com), SciVerse Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Senior Manager, Corporate Relations, Elsevier
More by this Source
Elsevier and Energy Institute Work Together to Publish Journal of the Energy Institute
Mar 06, 2014, 07:13 ET
Elsevier Unveils New Digital Platform for Expert Consult, Student Consult
Mar 06, 2014, 07:06 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.